BioCryst surges on upbeat PhII gout data; IDEXX buys research/lab in $43M deal;

 @FierceBiotech: Blockbuster breakup: Amylin buys out Lilly's exenatide rights in $1.6B deal. News | Follow @FierceBiotech

 @JohnCFierce: Key AZ/Targacept depression drug flunks first Phase III test. Item | Follow @JohnCFierce

 @RyanMFierce: Medidata (SaaS clinical trials software) reports profits up in 3Q, 33 new customers, $MDSO up 2.04%. Release | Follow @RyanMFierce

 @MaureenFierce: Nabi will explore strategic options after its anti-smoking vaccine NicVAX failed in a second Phase III trial. Article | Follow @MaureenFierce

> Shares of BioCryst Pharmaceuticals surged on positive mid-stage results for its experimental gout therapy. The results set the stage for a Phase III program. Report

> IDEXX Laboratories has struck a deal to buy a research and diagnostic lab business from the University of Missouri for $43 million. Report

> NeurogesX announced positive top-line results from its Phase II clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia. Release

> Insmed reported that the clinical hold on its late-stage lung drug spurred a bigger-than-expected loss for the last quarter. Story

Pharma News

 @FiercePharma: Integrating Cephalon, Teva eyes up to 1,500 job cuts. News | Follow @FiercePharma

> Key antidepressant from AZ/Targacept fails trial. Report

> AZ launches Crestor co-pay card to battle. Story

> Lipitor copies Amid FCPA probe, AZ indicted in Serbia for bribery. Article

Biotech Research News

> Eliminating 'senescent' cells in mice delayed age-related ailments. News

> Stem cell therapy for Parkinson's works wells in two animal models. Story

> Scripps breakthrough unlocks the potential of a promising cancer drug class. More

Manufacturing News

> Plant check reveals Genentech report flaw repeat. Article

> Pharma recalls up 54% in Q3. Item

> MedImmune cell-culture plant named facility of the year. Story

And Finally... Investigators at three sites in the U.S. are studying an experimental retroviral gene therapy from Tocagen for glioblastomas. Story